Can diuretics be used in a patient with chronic kidney disease stage 4 (eGFR 15–29 mL/min/1.73 m²)?

Yes, diuretics can and should be used in CKD stage 4 for appropriate indications

Diuretics are effective and indicated in CKD stage 4 (eGFR 15-29 mL/min/1.73 m²) for managing hypertension and volume overload, with thiazide-like diuretics (particularly chlorthalidone) and loop diuretics both demonstrating efficacy at this level of kidney function.

Primary Indications in CKD Stage 4

Hypertension Management

• Thiazide-like diuretics (chlorthalidone) are effective for blood pressure control even in advanced CKD, challenging the outdated belief that thiazides lose efficacy at lower GFR 1, 2
• Loop diuretics serve as reasonable second- or third-line antihypertensive options 1
• Diuretics can be used alongside RAS inhibitors, SGLT2 inhibitors, and other guideline-directed therapies without diminishing their benefits 2

Volume Overload

• Loop diuretics are the primary agents for managing volume overload when GFR falls below 30 mL/min/1.73 m² 3
• Combination therapy with thiazides and loop diuretics may be necessary for diuretic-resistant volume overload 3

Specific Diuretic Selection Algorithm

For hypertension in CKD stage 4:

1. Start with chlorthalidone (thiazide-like diuretic) as it has proven efficacy in stage 4 CKD 1, 2
2. Add or switch to loop diuretics if volume overload is present or blood pressure remains uncontrolled
3. Consider mineralocorticoid receptor antagonists (spironolactone) for treatment-resistant hypertension, though hyperkalemia risk limits use 1

For volume overload in CKD stage 4:

1. Loop diuretics are first-line (furosemide, torsemide, bumetanide) 3
2. Escalate doses as needed—higher doses are often required as GFR declines
3. Add thiazide-like diuretic for synergistic effect if loop diuretic alone is insufficient 3

Critical Monitoring Requirements

When prescribing diuretics in CKD stage 4, monitor closely for:

• Electrolytes: Check potassium, sodium, magnesium within 2-4 weeks of initiation or dose changes 2
• Renal function: Expect transient eGFR decline (hemodynamic effect), but monitor for excessive drops or AKI 2
• Volume status: Assess symptoms, weight, urine output, and physical exam findings regularly
• Blood pressure: Avoid excessive hypotension, particularly in elderly or frail patients

Important Caveats and Safety Considerations

Thiazide Diuretics in Advanced CKD

The CLICK trial specifically demonstrated that chlorthalidone reduces blood pressure in stage 4 CKD, providing strong evidence for use at eGFR 15-29 mL/min/1.73 m² 1, 2. This contradicts older teaching that thiazides are ineffective below eGFR 30.

Loop Diuretics and Outcomes

Recent evidence suggests loop diuretics may be associated with higher mortality in advanced CKD, though they don't accelerate progression to ESKD 4. This underscores the importance of using the lowest effective dose and reassessing need regularly.

Adverse Effects to Anticipate

• Electrolyte disturbances: Hyponatremia, hypokalemia, hypomagnesemia, or hyperkalemia (when combined with RAS inhibitors or MRAs) 2, 5
• Metabolic changes: Diuretics alter proximal tubular metabolism and increase ammoniagenesis 5
• AKI risk: Particularly with aggressive diuresis or volume depletion 2
• Neurohormonal activation: May worsen with chronic use 6

Integration with Other CKD Therapies

Diuretics complement rather than compete with guideline-directed CKD therapies:

• RAS inhibitors: Continue ACEi/ARB even when eGFR falls below 30 mL/min/1.73 m² per KDIGO 2024 guidelines 7. Diuretics can potentiate RAS blockade effects 8
• SGLT2 inhibitors: Can be used down to eGFR ≥20 mL/min/1.73 m² 7. Concomitant diuretic use does not diminish SGLT2i benefits 2
• Nonsteroidal MRAs: Recommended for eGFR >25 mL/min/1.73 m² with appropriate potassium monitoring 7

Practical Dosing Considerations

In CKD stage 4, higher diuretic doses are typically required:

• Loop diuretics: May need 2-3 times the dose used in normal kidney function
• Chlorthalidone: Standard doses (12.5-25 mg daily) remain effective 1
• Combination therapy: Chlorthalidone can mitigate hyperkalemia risk when using spironolactone, but requires careful monitoring 1

When to Reduce or Stop Diuretics

Deprescribe or reduce diuretics when:

• Euvolemia is achieved and maintained
• Blood pressure is controlled with other agents
• Patient develops symptomatic hypotension
• Severe electrolyte abnormalities occur despite management
• Approaching dialysis initiation (eGFR <15 mL/min/1.73 m²) and volume control becomes inadequate

The key principle is to use diuretics when congestion or uncontrolled hypertension is present, but minimize exposure once clinical targets are met, as chronic diuretic use without objective indication may cause harm 6.